Clinical Trial Update: AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating AK104 in combination with TACE for resectable hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Resectable Hepatocellular Carcinoma

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Resectable Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN